Trial Profile
A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Setanaxib (Primary)
- Indications Diabetic nephropathies; Renal fibrosis
- Focus Therapeutic Use
- 07 Jul 2021 Planned number of patients changed from 142 to 92.
- 07 Jul 2021 Planned End Date changed from 1 Jul 2020 to 30 Jun 2022.
- 27 Jan 2021 According to a GenKyoTex media release, to date, 29 patients have completed the full 48-week treatment and no safety signals have been identified.